Key statistics
Open | 5.20 |
---|---|
High | 5.20 |
Low | 4.90 |
Bid | 0.505 |
Offer | 0.56 |
Previous close | 5.05 |
Average volume | -- |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Jan 06 2023.
More ▼
Announcements
- Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis
- Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health
- Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds
- Can-Fite Provides Namodenoson Patent Update
- Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on August 8
- Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer
- Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson
- Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds
More ▼